Grifols, S.A. (NASDAQ:GRFS) Declares $0.09 Special Dividend

Grifols, S.A. (NASDAQ:GRFS) announced a special dividend on Monday, June 22nd. Investors of record on Thursday, July 2nd will be given a dividend of 0.0945 per share by the biotechnology company on Thursday, July 9th. The ex-dividend date of this dividend is Thursday, July 2nd.

Grifols has a payout ratio of 12.7% meaning its dividend is sufficiently covered by earnings. Research analysts expect Grifols to earn $1.34 per share next year, which means the company should continue to be able to cover its $0.14 annual dividend with an expected future payout ratio of 10.4%.

Grifols Price Performance

Shares of GRFS stock traded down $0.10 during midday trading on Tuesday, reaching $7.17. 429,640 shares of the company were exchanged, compared to its average volume of 652,838. Grifols has a 12 month low of $7.16 and a 12 month high of $11.14. The company has a debt-to-equity ratio of 1.16, a quick ratio of 0.85 and a current ratio of 2.47. The company has a market cap of $4.88 billion, a P/E ratio of 37.76, a PEG ratio of 0.29 and a beta of 0.65. The company’s 50 day moving average price is $7.92 and its two-hundred day moving average price is $8.51.

Grifols (NASDAQ:GRFS) last issued its earnings results on Saturday, February 14th. The biotechnology company reported $0.38 earnings per share (EPS) for the quarter. Grifols had a net margin of 5.54% and a return on equity of 6.21%. The company had revenue of $2.32 billion during the quarter. On average, sell-side analysts expect that Grifols will post 1.06 earnings per share for the current year.

Grifols Company Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.